Europe's main stock markets were mixed in early trading on Friday, as corporate earnings were greeted with mixed reviews.
In Paris, the CAC 40 lost 0.79% to 6,834.52 points at around 07:49 GMT. In London, the FTSE 100 lost 0.16%, while in Frankfurt, the Dax advanced by 0.03%.
The EuroStoxx 50 index was down by 0.28%, the FTSEurofirst 300 by 0.34% and the Stoxx 600 by 0.12%.
After Alstom, Worldline and Plastic Omnium, the Paris Bourse saw further profit warnings, with Remy Cointreau (-7.21%) drastically lowering its targets for 2023-2024, and Sanofi plunging 13.65% due to cautious targets for 2024 and 2025 against a backdrop of increased R&D investment and higher taxes.
The European healthcare sector also suffered the sharpest sectoral decline (-1.04%).
Leading the Stoxx 600, lighting manufacturer Signify
climbed 11.75% after reporting better-than-expected quarterly results.
(Written by Blandine Hénault, edited by Kate Entringer)
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
SANOFI 
